TLSI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TriSalus Life Sciences Inc (TLSI) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has positive growth in revenue and a bullish analyst rating, the stock's technical indicators are bearish, and recent financial performance shows a significant drop in net income. Additionally, there are no strong trading signals or significant catalysts to suggest immediate upside potential. A hold position is recommended until clearer positive trends emerge.
The MACD is slightly positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 43.163, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting the stock is in a downtrend. The current price of $4.92 is near the pivot level of $4.804, with key resistance at $5.125 and support at $4.483. Overall, the technical indicators do not suggest a strong buy signal.
The appointment of Michael P. Stansky, with 40 years of healthcare investment experience, as a board member could provide strategic insights and improve capital market performance. The company's PEDD™ platform shows potential for improving treatment outcomes for patients with solid tumors. Revenue growth of 59.79% YoY in Q4 2025 is a positive indicator of business expansion.
Net income dropped to 0 in Q4 2025, representing a 100% YoY decline. Gross margin decreased by 2.06% YoY, and EPS remains negative at -0.96 despite improvement. The stock's bearish technical indicators and lack of significant trading trends from hedge funds or insiders further dampen the outlook.
In Q4 2025, revenue increased by 59.79% YoY to $13.2 million, showing strong top-line growth. However, net income dropped to 0, down 100% YoY, indicating profitability challenges. EPS improved to -0.96, up 140% YoY, but remains negative. Gross margin dropped slightly to 83.52%, down 2.06% YoY, reflecting some pressure on operational efficiency.
Canaccord analyst William Plovanic raised the price target from $11 to $12 and maintained a Buy rating, citing bullishness on the Med-Tech sector due to strong demand, M&A activity, and a favorable market environment. This reflects a positive long-term outlook for the stock.
